ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
CohBar, NIAID to assess CB5064 Analogs for Covid-19 treatment pharmaceutical-technology
January 13, 2021CohBar and the US National Institute of Allergy and Infectious Diseases (NIAID) have signed a non-clinical evaluation agreement (NCEA) to analyse CB5064 Analogs for treating Covid-19 related Acute Respiratory Distress Syndrome (ARDS).
Pharma Sources Insight January 2025
